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Abstract Human transmembrane tumor necrosis factor (pro-
TNF) was examined for protein acylation. The cDNA encoding
pro-TNF was expressed in both COS-1 cells and Sf9 cells and
metabolic labeling with [3H]myristic or [3H]palmitic acid was
attempted. The 17 kDa mature TNF secreted from the
transfected cells was not labeled, whereas the 26 kDa pro-TNF
was specifically labeled with [3H]palmitic acid. The [3H]palmitic
acid labeling of pro-TNF was eliminated by treatment with
hydroxylamine, indicating that the labeling was due to palmi-
toylation of a cysteine residue via a thioester bond. Site-directed
mutagenesis of the two cysteine residues residing in the leader
sequence of pro-TNF demonstrated that palmitoylation of
pro-TNF occurs solely at Cys-47, located at the boundary
between the transmembrane and cytoplasmic domains of pro-
TNF. Thus, pro-TNF interacts with the plasma membrane via
both its proteinaceous transmembrane domain and a lipid
anchor. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Tumor necrosis factor (TNF) is an extremely pleiotropic
pro-in£ammatory cytokine with a wide range of biological
e¡ects [1]. This protein is initially synthesized and expressed
as a biologically active transmembrane prohormone (pro-
TNF), linked to the membrane via the leader sequence. Syn-
thesis of TNF begins with an unusually long 76 amino acid
propeptide sequence. This leader sequence does not serve as a
typical N-terminal signal sequence during processing and in-
tracellular targeting [2]. Rather, the leader sequence functions
as a signal-anchor sequence, and synthesis and insertion into
the endoplasmic reticulum (ER) membrane occur cotransla-
tionally. Then, probably via Golgi-mediated transfer, TNF
appears on the plasma membrane as a trimeric, type II trans-
membrane protein [3]. Finally, pro-TNF cleavage occurs at
the outer surface of the plasma membrane, probably by a
metallo-proteinase [4,5], and/or other enzyme to release ma-
ture, soluble trimeric TNF.
The transmembrane form of TNF (pro-TNF) was found to
be biologically active and can transduce signals to adjacent
cells by cell^cell contact [6]. In fact, pro-TNF is superior to
mature TNF in activating the human p80 TNF receptor for a
number of cellular functions [7]. In addition, recent reports
revealed that the pro-TNF functions not only as an activating
ligand but also as a receptor that transmits reverse signals
from TNF receptor [8]. In human monocytes/macrophages,
reverse signaling through pro-TNF confers resistance to lipo-
polysaccharide [9]. It was also demonstrated that reverse sig-
naling through pro-TNF induced E-selectin expression on ac-
tivated human CD4 T-cells [10]. Thus, biological activities of
26 kDa transmembrane TNF are distinct from that of the 17
kDa secretory form of TNF and this characteristic activity of
pro-TNF is mediated by the 76 residue leader sequence of this
molecule. However, the precise role of this leader sequence on
the function of pro-TNF has not been well characterized.
With regard to the mechanism of reverse signaling through
pro-TNF, Watts et al. provided evidence that casein kinase I
phosphorylates the cytoplasmic domain of pro-TNF at a con-
sensus sequence that is conserved among members of the TNF
family [8]. In this study, to reveal the possible involvement of
other co- or post-translational protein modi¢cations in the
expression and cellular processing of pro-TNF, acylation of
pro-TNF was examined by metabolic labeling of the COS-1
cells or Sf9 cells transfected with cDNA encoding pro-TNF.
As a result, pro-TNF was found to be palmitoylated at a
speci¢c cysteine residue located at the boundary between the
transmembrane and cytoplasmic domains.
2. Materials and methods
2.1. Materials
Restriction endonucleases, DNA modifying enzymes, RNase inhib-
itor, and Taq DNA polymerase were purchased from Takara Shuzo,
Kyoto Japan. RNase was purchased from Boehringer-Mannheim,
Germany. [3H]leucine, [3H]myristic acid, [3H]palmitic acid and Am-
plify were from Amersham, UK. The Dye Terminator Cycle Sequenc-
ing kit was from Applied Biosystems, USA. Anti-human TNF poly-
clonal antibody was purchased from RpD systems, USA. Protein G
Sepharose was from Pharmacia Biotech, Sweden. Other reagents pur-
chased from Wako Pure Chemical, Daiichi Pure Chemicals, and Sei-
kagaku Kogyo (Japan) were of analytical or DNA grade.
2.2. Plasmid construction
Plasmid pBluescript II SK(+) lacking ApaI and HindIII sites was
constructed as previously described [11], and designated pB. Plasmid
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pBpro-TNF, which contains the full-length human pro-TNF cDNA,
and plasmid pBV2G,R3A-TNF, containing a cDNA encoding the N-
myristoylated mutant of the mature domain of TNF, were con-
structed as described [11,12]. Plasmids pBC-47A-pro-TNF and pBC-
28A-pro-TNF were constructed by utilizing polymerase chain reaction
(PCR). For this procedure, pBpro-TNF served as a template and two
mutagenic primers (C-47A, 5P-ATATGGGCCCCAGGGCTCCAG-
GCGGGCCTTGTTCC-TCAGCCTC-3P ; C-28A, 5P-ATATGGCGC-
CACCACGCTCTTCGCCCTGCTGCACTTT-GGA-3P) and B1(5P-
GCCGGGATCCTAGGGCGAATTGGGTACC-3P) as primers. For
plasmid pBC-47A-pro-TNF, after digestion with ApaI and EcoRI, the
ampli¢ed product was subcloned into pBpro-TNF at ApaI and EcoRI
sites. For plasmid pBC-28A-pro-TNF, after digestion with NarI and
EcoRI, the ampli¢ed product was subcloned into pBpro-TNF at NarI
and EcoRI sites. Plasmids pcDNA3 containing mutant pro-TNF
cDNAs used for transfection of COS-1 cells were constructed as fol-
lows; The BamHI/EcoRI fragments containing each of the mutant
pro-TNF cDNA were excised from each of the pB vectors containing
mutant pro-TNF cDNAs and then ligated to the BamHI/EcoRI sites
of pcDNA3. Construction of recombinant transfer vector (pAcYM1)
containing pro-TNF cDNA used for baculovirus expression system
was performed as previously described [13]. The DNA sequences of
these recombinant cDNAs were con¢rmed by the dideoxy-nucleotide
chain termination method [14].
2.3. Transfection of COS-1 cells and determination of acylated proteins
The simian virus 40-transformed African Green monkey kidney cell
line, COS-1, was maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM, Gibco BRL) supplemented with 10% fetal calf serum (FCS,
Gibco BRL). Cells (2U105) were plated onto 35 mm diameter dishes
1 day before transfection. pcDNA3 construct (2 Wg; Invitrogen, San
Diego, CA, USA) containing mutant TNF cDNA was used to trans-
fect each plate of COS-1 cells along with 4 Wl of Lipofectamine (2 mg/
ml; Gibco BRL) in 1 ml of serum-free medium. After incubation for
5 h at 37‡C, the cells were refed with serum containing medium and
incubated again at 37‡C for 48 h. The cells were then washed twice
with 1 ml of serum-free DMEM and incubated for 5 h in 1 ml of
DMEM with 2% FCS containing [3H]leucine (30 WCi/ml), [3H]myristic
or palmitic acid (100 WCi/ml). In this case, leucine-free DMEM was
used for the labeling with [3H]leucine. Subsequently, the cells were
washed three times with Dulbecco’s phosphate-bu¡ered saline
(DPBS) and collected with cell scrapers, followed by lysis with 200
Wl of RIPA bu¡er (50 mM Tris^HCl (pH 7.5), 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sul-
fate (SDS), proteinase inhibitors) on ice for 20 min. The cell lysates
were centrifuged at 15 000 rpm at 4‡C for 15 min in a microcentrifuge
(Hitachi-CF15D2) and supernatants were collected. The samples were
immunoprecipitated with a speci¢c goat anti-hTNF polyclonal anti-
body (RpD Systems) as described [11] and then analyzed by SDS^
polyacrylamide gel electrophoresis (PAGE) and £uorography.
2.4. Virus and Sf9 cells
AcVAPK6, used as an expression vector in this study, contains
Escherichia coli L-galactosidase (Lac Z) gene in place of the poly-
hedrin gene of Autographa californica nuclear polyhedrosis virus
(AcNPV). AcVAPK6 and recombinant baculovirus were propagated
in Spodoptera frugiperda (Sf) cells at 28‡C in TC100 medium supple-
mented with 10% FCS. Sf9 cells were subcultured when the cell den-
sity reached 2^2.5U106 cells/ml, two or three times a week.
2.5. Transfection and selection of recombinant baculovirus
AcVAPK6 baculovirus DNA was linearized by digestion with
Eco81I to increase the level of recombination. The AcVAPK6 and
pAcYM1 with pro-TNF cDNA were cotransfected into Sf9 cells
with lipofectin (Gibco BRL). The lipofectin mixture (8 Wl lipofectin
and 4 Wl water) was added dropwise to 12 Wl of the cotransfection
mixture containing 1 Wg of pAcYM1 with pro-TNF cDNA and 50 ng
of linearized AcVAPK6 baculovirus DNA, and incubated for 15 min
at room temperature. The mixture was inoculated into a 35 mm tissue
culture dish containing 1.5U106 Sf9 cells in 1 ml of serum-free TC100
and incubated for 4 h at 28‡C. 1 ml of TC100 with 10% FCS was then
added to the cells, and the supernatant was harvested after a 96 h
incubation. Recombinant virus was puri¢ed by plaque forming assay.
Plaques with a white phenotype were picked up and puri¢ed repeat-
edly until no blue plaques could be detected.
2.6. Determination of acylated proteins expressed in Sf9 cells
Sf9 cells (1.5U106) in 35 mm tissue culture dishes were infected
with virus at a multiplicity of infection of one plaque forming unit
per cell at 28‡C. After incubation for 48 h, cells were washed twice
with 1 ml of FCS-free TC100 and cultured for 3 h in 1 ml of TC100
with 2% FCS containing [3H]myristic or palmitic acid (150 WCi/ml).
The cells were washed three times with NPV-PBS (140 mM NaCl, 26
mM KCl, 8 mM Na2HPO4, 1 mM KH2PO4) and then lysed with
RIPA bu¡er on ice for 20 min. The cell lysates were centrifuged at
15 000 rpm at 4‡C for 15 min in a microcentrifuge (Hitachi-CF15D2)
and supernatants were collected.
2.7. Western blotting
The total cell lysates of each group of transfected cells were resolved
by 12.5% SDS^PAGE and then transferred to an Immobilon-P trans-
fer membrane (Millipore). After blocking with non-fat milk, the mem-
brane was probed with a speci¢c goat anti-hTNF antibody as de-
scribed previously [15]. Immunoreactive proteins were speci¢cally
detected by incubation with horseradish peroxidase-conjugated anti-
goat IgG antibody (Santa Cruz). The membrane was developed with
enhanced chemiluminescence (ECL) Western blotting reagent (Amer-
sham Corp.) and exposed to an X-ray ¢lm (Kodak).
2.8. SDS^PAGE and £uorography
Samples were denatured by boiling for 3 min in SDS-sample bu¡er
followed by analysis by SDS^PAGE on a 12.5% gel. Thereafter, the
gel was ¢xed and soaked in Amplify1 (Amersham) for 30 min. The
gel was dried under vacuum and exposed to an X-ray ¢lm (Kodak)
for an appropriate period.
3. Results
3.1. Transmembrane TNF is palmityolated
To determine possible protein acylation of the transmem-
brane form of TNF (pro-TNF), COS-1 cells transfected with
human pro-TNF cDNA were metabolically labeled with
[3H]leucine, [3H]myristic acid and [3H]palmitic acid. The
labeled pro-TNFs were immunoprecipitated from total cell
lysates and subjected to SDS^PAGE and £uorography.
V2G,R3A-TNF, an N-myristoylated mutant of mature
TNF, which is known to be e⁄ciently N-myristoylated [12]
was subjected to the same procedure. Western blotting of the
total cell lysates revealed that TNF was not expressed in con-
trol COS-1 cells as shown in Fig. 1B, lanes 2^4. When pro-
TNF cDNA was transfected into COS-1 cells, a remarkable
amount of 26 kDa pro-TNF and a trace amount of a pro-
cessed form of TNF (17 kDa) were detected (Fig. 1B, lanes
5^7). The expression of these two TNF species was con¢rmed
by the metabolic labeling with [3H]leucine as shown in Fig.
1A, lane 4. Metabolic labeling with [3H]myristic acid and
[3H]palmitic acid revealed that 26 kDa pro-TNF was speci¢-
cally labeled with [3H]palmitic acid. In the case of V2G,R3A-
TNF, e⁄cient expression of 17 kDa TNF was detected by
Western blotting (Fig. 1B, lanes 8^10) and by metabolic label-
ing with [3H]leucine (Fig. 1A, lane 7). Metabolic labeling with
[3H]myristic acid and [3H]palmitic acid revealed that
V2G,R3A-TNF is speci¢cally labeled with [3H]myristic acid,
but no incorporation of [3H]palmitic acid was observed as
shown in Fig. 1A, lanes 8 and 9. These results strongly in-
dicated that 26 kDa pro-TNF is not N-myristoylated, but
palmitoylated.
To con¢rm palmitoylation of pro-TNF in a di¡erent ex-
pression system, pro-TNF expressed in Sf9 cells by the bacu-
lovirus expression system was examined for protein acylation.
As shown in Fig. 2A, 26 kDa pro-TNF was strongly ex-
pressed and a trace amount of a processed form of TNF
(17 kDa) were detected, as was the case with COS-1 cells
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when pro-TNF cDNA was transfected into Sf9 cells. Meta-
bolic labeling with [3H]myristic acid and [3H]palmitic acid
revealed that 26 kDa pro-TNF is speci¢cally labeled with
[3H]palmitic acid as shown in Fig. 2B. These results clearly
indicated that transmembrane TNF expressed in Sf9 cells was
also palmityolated.
Next we determined the chemical nature of the linkage be-
tween the fatty acid and pro-TNF. To distinguish between a
labile thioester linkage and a stable amide bond, we examined
whether the [3H]palmitic acid labeling of pro-TNF expressed
in COS-1 cells was sensitive to hydroxylamine. As shown in
Fig. 3, treatment of the SDS^PAGE gel with neutral 1 M
hydroxylamine completely removed both [3H]palmitic acid
and [3H]myristic acid labeling of pro-TNF. The fact that the
[3H]myristic acid labeling of pro-TNF was sensitive to hy-
droxylamine suggested that the low level of [3H]myristic
acid incorporation could be explained by chain elongation
of myristic acid to palmitic acid. In contrast, [3H]leucine label-
ing of pro-TNF and V2G,R3A-TNF and [3H]myristic acid
labeling of V2G,R3A-TNF were not a¡ected by the hydroxyl-
amine treatment. These results indicated that the palmitic acid
was esteri¢ed to a cysteine residue of pro-TNF.
3.2. Palmitoylation of pro-TNF occurs speci¢cally at Cys-47,
located at the boundary between the transmembrane and
cytoplasmic domains of pro-TNF
Next we established the speci¢c cysteine palmitoylation site
of pro-TNF. To detemine whether the palmitoylation site is
located at the leader sequence of pro-TNF or in the mature
domain of TNF, [3H]palmitic acid labeling of secreted mature
Fig. 1. Transmembrane TNF is palmitoylated. Pro-TNF and V2G,R3A-TNF were expressed in COS-1 cells and the cells were labeled with
[3H]leucine (Leu), [3H]palmitic acid (Pal) or [3H]myristic acid (Myr). A: The labeled proteins in total cell lysates of each cells were immunopre-
cipitated with anti-TNF antibody. Samples were then subjected to SDS^PAGE and £uorography. B: Total cell lysates of each cells were di-
rectly analyzed by Western blotting using anti-TNF antibody.
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TNF was examined. COS-1 cells transfected with human pro-
TNF cDNA were labeled with [3H]leucine and [3H]palmitic
acid. The labeled TNF was immunoprecipitated from total
cell lysates and cell culture supernatants and then subjected
to SDS^PAGE and £uorography. As shown in Fig. 4, lanes 1
and 2, a large amount of 17 kDa mature TNF was found to
be secreted in the culture supernatants. However, no
[3H]palmitic acid incorporation was observed on this secreted
TNF molecule (lane 4), indicating that the palmitoylation site
is located in the leader sequence of pro-TNF.
Since two cysteine residues (Cys-47, Cys-28) are located in
the leader sequence of pro-TNF, we next determined which
cysteine residue was palmitoylated. For this purpose, two mu-
tant pro-TNFs, C-47A-pro-TNF and C-28A-pro-TNF, in
which Cys-47 or Cys-28 in pro-TNF was replaced with Ala,
were generated and their susceptibility to protein palmitoyla-
tion was evaluated in the COS cell expression system. Western
blotting analysis of total cell lysates and cell culture super-
natants of each of the transfected cells revealed that e⁄cient
expression of pro-TNF and e⁄cient secretion of mature TNF
was equally observed with C-47A-pro-TNF and C-28A-pro-
TNF as compared with wild type pro-TNF as shown in Fig.
5A,C. [3H]palmitic acid labeling of these transfected cells re-
vealed that replacement of Cys-47 with Ala completely inhib-
ited the labeling, whereas that of Cys-28 did not a¡ect the
labeling (Fig. 5B). These results indicated that Cys-47 of
pro-TNF was essential for the attachment of palmitic acid,
most likely because the Cys residue was the speci¢c site of
covalent attachment of palmitic acid. Thus, site-directed mu-
tagenesis of the two cysteine residues residing in the leader
sequence of pro-TNF demonstrated that palmitoylation of
pro-TNF occurs solely at Cys-47, located at the boundary
between the transmembrane and cytoplasmic domains of
pro-TNF.
4. Discussion
A number of eukaryotic cellular proteins are covalently
modi¢ed with long-chain fatty acids such as myristic and pal-
mitic acids [16^20]. Many of these acylated proteins play key
roles in regulating cellular structure and function. N-Myris-
toylation is the result of cotranslational addition of the satu-
rated 14-carbon fatty acid myristate to a glycine residue at the
extreme N-terminus after removal of the initiating methio-
nine. A stable amide bond links myristate irreversibly to pro-
teins. Unlike N-myristoylation, palmitoylation is a reversible
post-translational modi¢cation of proteins with the saturated
16-carbon fatty acid palmitate. Palmitate is usually linked to
cysteine residues through a thioester bond. The identity of the
enzyme responsible for protein palmitoylation has not been
¢rmly established yet. Therefore, neither precise substrate spe-
ci¢city nor the consensus amino acid sequence recognized by
Fig. 2. Transmembrane TNF expressed in Sf9 cells by vaculovirus
expression system is also palmitoylated. Pro-TNF was expressed in
Sf9 cells by vaculovirus expression system and the cells were labeled
with [3H]palmitic acid (Pal) or [3H]myristic acid (Myr). A: Total
cell lysates of each cells were analyzed by Western blotting using
anti-TNF antibody. B: The labeled proteins in total cell lysates of
each cells were immunoprecipitated with anti-TNF antibody. Sam-
ples were then subjected to SDS^PAGE and £uorography.
Fig. 3. Palmitic acid is bound to transmembrane TNF through thio-
ester linkage. Pro-TNF and V2G,R3A-TNF were expressed in COS-
1 cells and the cells were labeled with [3H]leucine (Leu), [3H]palmitic
acid (Pal) or [3H]myristic acid (Myr). The labeled proteins in total
cell lysates of each cells were immunoprecipitated with anti-TNF
antibody. Samples were then subjected to SDS^PAGE. After ¢xa-
tion with 30% methanol/7% acetic acid for 1 h, the gel was washed
three times with distilled water, soaked for 8 h in either 1 M hy-
droxylamine pH 7.5 or 1 M Tris pH 7.5, then prepared for £uorog-
raphy.
Fig. 4. Palmitoylation site is located in the leader sequence of trans-
membrane TNF. Pro-TNF was expressed in COS-1 cells and the
cells were labeled with [3H]leucine (Leu) or [3H]palmitic acid (Pal).
The labeled proteins in total cell lysates or cell culture supernatants
of each cells were immunoprecipitated with anti-TNF antibody.
Samples were then subjected to SDS^PAGE and £uorography.
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this enzyme has been elucidated to date. To complicate mat-
ters, there are numerous reports documenting the existence of
non-enzymatic palmitoylation of proteins.
In integral membrane proteins the acylated cysteine residues
are always located at the boundary between the transmem-
brane region and the cytoplasmic tail of the respective protein
[21]. In the present study, we revealed that the human trans-
membrane TNF was palmitoylated at a speci¢c cysteine resi-
due, Cys-47, located at the boundary between the transmem-
brane and cytoplasmic domains of pro-TNF, consistent with
the previous observations. When the amino acid sequences of
15 pro-TNF molecules derived from di¡erent species are sur-
veyed, Cys-47 is conserved in all pro-TNF species, suggesting
the critical role of this modi¢cation in the physiology of pro-
TNF.
Concerning the acylation of pro-TNF, it was previously
reported that the 26 kDa pro-TNF was myristoylated in hu-
man monocytes and that the acylation occurred via amide
bond formation with two speci¢c O-amino groups of internal
lysine residues(Lys-58, Lys-57) present within the 76 residue
leader sequence of pro-TNF [22]. In the present study, how-
ever, metabolic labeling of COS-1 cells and Sf9 cells trans-
fected with pro-TNF cDNA clearly demonstrated that the
pro-TNF was not myristoylated via an amide bond, but was
palmitoylated through the thioester bond at a speci¢c Cys
residue Cys-47. One possible explanation for this discrepancy
is that the di¡erence in the expression of speci¢c lysyl N-O-
NH2-myristoyl transferase that is responsible for the myris-
toylation of lysine residues of pro-TNF in di¡erent cell types.
Since TNF is expressed in various cell types such as mono-
cyte/macrophages, T-cells, B-cells, neutrophils, astrocytes, en-
dothelial cells, smooth muscle cells etc. [1], the status of pro-
tein acylation of pro-TNF might be di¡erent depending on the
cell types that express pro-TNF.
Physiological roles of protein palmitoylation of soluble cy-
toplasmic proteins and of peripheral membrane proteins have
been well characterized with the Src family of tyrosine protein
kinases and K subunits of heterotrimeric G proteins [23^27].
In these proteins, palmitoylation is involved in the reversible
membrane binding, speci¢c membrane targeting, as well as
regulated transmembrane signaling of proteins. As compared
with these soluble proteins, the role of palmitoylation of in-
Fig. 5. Palmitoylation of transmembrane TNF occurs speci¢cally at Cys-47. Pro-TNF, C-47A-pro-TNF and C-28A-pro-TNF were expressed in
COS-1 cells and the cells were labeled with [3H]palmitic acid. Total cell lysates (A) or cell culture supernatants (C) of each cells were analyzed
by Western blotting using anti-TNF antibody. The labeled proteins in total cell lysates of each cells were immunoprecipitated with anti-TNF
antibody. Samples were then subjected to SDS^PAGE and £uorography (B).
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tegral membrane proteins remains less well-established. In the
case of transferrin receptor and luteinizing hormone receptor,
palmitoylation has been reported to regulate the rate of inter-
nalization of these receptors [28,29]. Therefore it is possible
that palmitoylation of pro-TNF is involved in regulation of
internalization or recycling of this molecule. It is also possible
that palmitoylation a¡ects shedding of pro-TNF, thereby reg-
ulating secretion of the mature secretory form of TNF. How-
ever, since e⁄cient expression of pro-TNF and e⁄cient secre-
tion of mature TNF was observed with C-47A-pro-TNF, a
palmitoylation-de¢cient mutant of pro-TNF, as compared
with wild type pro-TNF as shown in Fig. 5, palmitoylation
of pro-TNF may not strongly a¡ect the ER membrane trans-
location, sorting to the plasma membrane and maturation of
pro-TNF.
Another possibility is the role in the signal transduction
through pro-TNF. In this regard, interesting observations
were recently reported on the role of palmitoylation on the
function of a transmembrane protein linker for activation of
T-cells (LAT) [30^32]. Mutation of the palmitoylation sites
within LAT prevents LAT partitioning to rafts, and reduces
LAT tyrosine phosphorylation as well as recruitment of LAT
binding proteins to rafts. Since accumulation and assembly of
signaling molecules in rafts is a critical step in T-cell signal
transduction, protein palmitoylation seems to play an impor-
tant role in T-cell signal transduction by speci¢cally recruiting
the signaling molecules to rafts. Since reverse signaling
through pro-TNF was found to operate in T-cells [10], it is
possible to speculate that the palmitoylation of pro-TNF
might participate in the signal transduction pathway of re-
verse signaling through pro-TNF.
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